We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave the company a Strong Buy Rating and a $9 Price...
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...
KRAS, one of the most mutated oncogenes across cancers, drives aggressive and treatment-resistant tumors. Silexion’s latest data highlights SIL-204’s ability to enhance first-line therapies...
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology with a focus on KRAS-driven cancers, among the most challenging targets in oncology. In collaboration with Evonik, Silexion...
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
December 11, 2024 -- InvestorsHub NewsWire -- via PESG Research -- The field of precision oncology has witnessed groundbreaking advancements in recent years, and Silexion Therapeutics (NASDAQ:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.19 | 177.611940299 | 0.67 | 3.45 | 0.575 | 116200796 | 2.38068546 | CS |
4 | -0.14 | -7 | 2 | 3.45 | 0.575 | 35763268 | 2.33618614 | CS |
12 | -0.57 | -23.4567901235 | 2.43 | 4.23 | 0.575 | 15581931 | 2.51462791 | CS |
26 | -34.14 | -94.8333333333 | 36 | 36.36 | 0.575 | 9015579 | 3.31121558 | CS |
52 | -34.14 | -94.8333333333 | 36 | 36.36 | 0.575 | 9015579 | 3.31121558 | CS |
156 | -34.14 | -94.8333333333 | 36 | 36.36 | 0.575 | 9015579 | 3.31121558 | CS |
260 | -34.14 | -94.8333333333 | 36 | 36.36 | 0.575 | 9015579 | 3.31121558 | CS |
Symbol | Price | Vol. |
---|---|---|
TCTMTCTM Kids IT Education Inc | US$ 0.764 (321.87%) | 729.72M |
NVDANVIDIA Corporation | US$ 120.07 (-3.67%) | 388.54M |
RIMEAlgorhythm Holdings Inc | US$ 0.02565 (5.12%) | 338.75M |
BHATBlue Hat Interactive Entertainment Technology | US$ 0.0355 (-11.25%) | 236.29M |
CLEUChina Liberal Education Holdings Ltd | US$ 0.1938 (30.77%) | 234.8M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions